Li-Kuo Su, Editor-in-Chief of Cancer Cell will join us at the Hotel Alimara, Monday 14 January 2013, 09:00 – 10:15, to deliver the 5th in VHIO´s prestigious series of VHIO Meet the Editors talks:
Cancer Cell and the Cancer Research Community
Related Posts
Josep Tabernero to serve as ESMO President 2018-2019
Source: ESMO Lugano, Switzerland, 23 June 2015 – The European Society for Medical Oncology (ESMO), the leading pan-European organisation in…
23 Jun 2015
Josep Tabernero listed among the Highly Cited Researchers 2016: representing some of the world´s most influential scientific minds
In the recently announced Highly Cited Researcher listing 2016 by Clarivate Analytics – formerly the IP & Science business of…
21 Nov 2016
VHIO´s Colorectal Task Force at ASCO: two studies first outing during the world´s most prestigious meeting in clinical oncology
• Promising results from a Phase II study evidence the clinical gains of combinatorial therapy with BRAF inhibitors for patients…
06 Jun 2016
Laura Soucek Awarded for Research Inhibiting Myc Tumor Activity
Principle Investigator of VHIO´s Mouse Models of Cancer Therapy Group, Laura Soucek has been awarded this year´s Fero (Fundación de Investigación Oncológica) grant for translational cancer research for her pioneering work using mouse models to counteract tumoral activity triggered by ´the oncogene from Hell´*, Myc.
29 Jun 2011
The ”la Caixa” Banking Foundation pays homage to medical researchers
Source: the ”la Caixa” Banking Foundation Josep Baselga, María Blasco, Valentí Fuster, Maite Mendioroz, Eduard Gratacós, Bonaventura Clotet and Pedro…
06 Sep 2017
The USP15 Biological Thermostat: a Promising Novel Therapeutic Target in Cancer
Barcelona, 19th February 2012.- After years studying the molecular bases of glioblastoma – the most common brain tumor and one of the most aggressive of all cancers, the group led by Dr. Joan Seoane , Director of Translational Research at the Vall d’Hebron Institute of Oncology (VHIO) and ICREA Research Professor has today published a study in Nature Medicine identifying USP15 as a critical protein in cancer which, thanks to its molecular characteristics, shows enormous therapeutic promise.
USP15 promotes tumor progression by activating the TGFβ pathway. Playing a highly significant oncogenic role in glioblastoma, TGFß is a powerful immunosuppressant allowing the tumor to escape the host immune system. It also acts as an angiogenic factor inducing blood vessels, promotes tumoral invasion, activates cancer stem cells, and in some tumors, induces metastases.
20 Feb 2012
VHIO and the Fritz Bender Foundation present latest advances in individualized cancer treatments
17th Fritz Bender Foundation International Symposium: Progress Towards Individualized Cancer Treatments, 07 – 09 November, 2013 To be inaugurated today,…
12 Nov 2013
VHIO genomic study identifies subgroups of HER2+ breast cancer with varying sensitivities to anti-HER2 treatment
• VHIO describes as many as four subgroups of HER2+ breast cancer (Luminal A, Luminal B, HER2-enriched and Basal-Like) with…
17 Jan 2014
Pertuzumab adds 16 months survival benefit to trastuzumab and chemotherapy treatment for HER2-positive metastatic breast cancer
Long-term follow-up from CLEOPATRA study presented at ESMO 2014 demonstrates ‘unprecedented’ benefit Lugano/Madrid, 28 September 2014 — Patients with HER2-positive…
29 Sep 2014
Novel anti-cancer agent proves effective against advanced ALK-positive non-small cell lung cancer (NSCLC)
Published today in The New England Journal of Medicine, a multi-center phase I clinical study conducted across 11 countries, co-authored by Enriqueta Felip, Principal Investigator of VHIO´s Thoracic Tumors Group, represents an important step forward in the treatment of patients with ALK-rearranged lung cancer.
27 Mar 2014
Spanish periodical EL MUNDO reveals its top 25 of the most influential Spanish Citizens in Medicine for 2014
Each year, in January, the Spanish periodical EL MUNDO publishes its selection of the 500 most influential Spanish citizens for that…
10 Jan 2014
Latest research unmasks six new susceptibility genes predisposing to ovarian cancer
Ovarian cancer ranks fifth among cancer-related death in women. While the exact cause of ovarian cancer remains largely unknown, up…
05 Feb 2015
Joint Vall d’Hebron University Hospital and VHIO project announced as Hinnovar Award finalist
The Hinnovar awards, organized by Novartis in collaboration with ESADE and the Spanish Society of Health Directives (SEDISA), aim to…
22 Nov 2013
VHIO paves the way for novel therapeutic strategy to revert resistance in colorectal cancer
Barcelona, 27 August, 2015.– Latest research published in Clinical Cancer Research by the Vall d´Hebron Institute of Oncology´s (VHIO) Stem…
27 Aug 2015
EU´s Horizon 2020 backs nanomedicine to potentiate therapy against pancreatic cancer
Nano-based drug delivery and anti-cancer therapy have shown great promise in recent years as potential novel weaponry in our arsenal…
05 Jul 2016
